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Parkin loss of function contributes to RTP801 elevation
and neurodegeneration in Parkinson’s disease
J Romanı´-Aumedes1, M Canal1, N Martı´n-Flores1, X Sun2, V Pe´rez-Ferna´ndez1, S Wewering3, R Ferna´ndez-Santiago4,5, M Ezquerra4,5,
C Pont-Sunyer4, A Lafuente1,5, J Alberch5,6, H Luebbert3, E Tolosa4,5, OA Levy7, LA Greene2 and C Malagelada*,1
Mutations in the PARK2 gene are associated with an autosomal recessive form of juvenile parkinsonism (AR-JP).
These mutations affect parkin solubility and impair its E3 ligase activity, leading to a toxic accumulation of proteins within
susceptible neurons that results in a slow but progressive neuronal degeneration and cell death. Here, we report that RTP801/
REDD1, a pro-apoptotic negative regulator of survival kinases mTOR and Akt, is one of such parkin substrates. We observed that
parkin knockdown elevated RTP801 in sympathetic neurons and neuronal PC12 cells, whereas ectopic parkin enhanced RTP801
poly-ubiquitination and proteasomal degradation. In parkin knockout mouse brains and in human fibroblasts from AR-JP
patients with parkin mutations, RTP801 levels were elevated. Moreover, in human postmortem PD brains with mutated parkin,
nigral neurons were highly positive for RTP801. Further consistent with the idea that RTP801 is a substrate for parkin, the two
endogenous proteins interacted in reciprocal co-immunoprecipitates of cell lysates. A potential physiological role for
parkin-mediated RTP801 degradation is indicated by observations that parkin protects neuronal cells from death caused by
RTP801 overexpression by mediating its degradation, whereas parkin knockdown exacerbates such death. Similarly, parkin
knockdown enhanced RTP801 induction in neuronal cells exposed to the Parkinson’s disease mimetic 6-hydroxydopamine and
increased sensitivity to this toxin. This response to parkin loss of function appeared to be mediated by RTP801 as it was
abolished by RTP801 knockdown. Taken together these results indicate that RTP801 is a novel parkin substrate that may
contribute to neurodegeneration caused by loss of parkin expression or activity.
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Parkinson’s disease (PD) is among the most frequent
neurodegenerative disorders, characterized by loss of spe-
cific populations of neurons in both the central and peripheral
nervous systems, including those in the substantia nigra pars
compacta (SNpc) and sympathetic ganglia.1–3 Although
treatments to ameliorate clinical manifestations of PD are
common, there are no pharmacological therapies to suppress
neuron degeneration and death.4
The PARK2 gene encodes for parkin protein. Parkin is an
E3 ligase and genetic mutations impair its enzymatic activity
and solubility. These PARK2 mutations are linked to the
appearance of an autosomal recessive form of juvenile
parkinsonism (AR-JP).5,6
Apart from mutations, parkin E3 ligase activity can be
inactivated both in vitro and in vivo by S-nitrosylation,7
oxidative stress8 and dopaminergic stress.9 The combination
of these stresses plus heterozygous parkin mutations can
also lead to earlier manifestations of parkinsonism.10
AR-JP symptomatology resembles sporadic PD, with loss of
neuromelanin positive (NMþ ) catecholaminergic neurons in
the SNpc and locus coeruleus.
Parkin overexpression or restoration of parkin activity in
culture or in animal models protects from various neurode-
generative conditions including mutant alpha synuclein,11
kainic acid12 and 6-hydroxydopamine (6-OHDA) toxicity.13,14
In Drosophila, parkin has been linked to protein translation by
interacting with the TSC/TOR/4EBP pathway.15 One
upstream regulator of the TSC/TOR/4EBP pathway is DDIT4,
a stress-regulated gene that encodes a protein designated
RTP801/REDD1 that negatively regulates the mechanistic
target of rapamycin (mTOR).16,17 In cellular models of PD,
DDIT4 was the most highly upregulated transcript (98-fold)
and its encoded protein, RTP801, was significantly induced.18
Moreover, RTP801 was upregulated in animal models of PD
and was elevated in NMþ neurons in the SNpc of idiopathic
PD patients in comparison with non-PD controls.19
RTP801 is both sufficient and necessary to mediate neuron
death in in vitro and in vivo models of PD.19 This involves a
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sequential mechanism in which it first blocks mTOR activation
and then, as a consequence, leads to the inactivation of the
neuronal survival kinase Akt, which is also an mTOR
substrate.20
As RTP801 protein has a very short cellular half-life
(2–5 min)21–23 and is subject to fine-tuned regulation,
we investigated whether parkin contributes to RTP801
degradation. We first explored whether RTP801 is a parkin
substrate, and second, whether parkin loss of function leads
to a toxic accumulation of RTP801 that could contribute to
neurodegeneration.
Results
RTP801 is degraded by the proteasome and poly-
ubiquitinated by parkin. Previous studies21–23 indicated
that RTP801 protein has a brief half-life, between 2 and 5 min.
Therefore, we first investigated how RTP801 is degraded
using HEK293 cells. Cultures were treated with epoxomycin, a
specific proteasome inhibitor, and chloroquine, an inhibitor of
intralysosomal catabolism. Western immunoblotting (WB)
indicated that RTP801 was degraded mostly by the protea-
some (Figure 1a). In nerve growth factor (NGF)-differentiated
PC12 cells, which model catecholaminergic neurons,24 we
observed similar results with epoxomycin. Chloroquine expo-
sure for 6 h, but not 30 h, mildly increased RTP801 levels
(Supplementary Figure S1). These data confirmed that
RTP801 degradation is mostly proteasomal in both HEK293
cells and NGF-differentiated PC12 cells.
Poly-ubiquitination involves three different enzymes, ubi-
quitin activator E1, ubiquitin transferor E2 and ubiquitin ligase
E3. It also requires the presence of lysines in the target
protein. RTP801 has six lysines that can be ubiquitinated. We
assessed whether RTP801 is poly-ubiquitinated in cells by
transfecting HEK293 cells either HA-tagged ubiquitin or with
both HA-ubiquitin and pCMS-eGFP RTP801. Twenty-four
hours after transfection, cultures were treated with epoxomy-
cin for at least 2 h, and then both endogenous and ectopic
RTP801 were immunoprecipitated. By WB, we detected high
molecular weight RTP801 species with different lengths of
poly-ubiquitin chains (HMW Ub-RTP801), for both endo-
genous (visible in the more exposed panel in Supplementary
Figure S2) and ectopic RTP801. Therefore, our data indicate
that RTP801 is poly-ubiquitinated and targeted to protea-
somal degradation in living cells (Supplementary Figure S2).
Such results raised the question of which E3 ligases poly-
ubiquitinate RTP801. One ligase particularly relevant to PD is
parkin. Therefore, we investigated whether RTP801 poly-
ubiquitination is enhanced by parkin, by transfecting HEK293
cells with RTP801 along with HA-ubiquitin and WT parkin or its
inactive form parkin DR2, lacking the RING2 domain. By
performing immunoprecipitation and WB, we detected high
molecular weight RTP801 species with poly-ubiquitin chains
(HMW Ub-RTP801) attached, and found that WT parkin but
not its DR2-truncated form, substantially increased RTP801
poly-ubiquitination (Figure 1b). Therefore, our data indicate
that RTP801 is poly-ubiquitinated in the presence of parkin
and targeted to proteasomal degradation in living cells.
To address whether parkin directly poly-ubiquitinates
RTP801, we used a cell-free assay. To reproduce the
sequential poly-ubiquitination reaction, we combined recom-
binant parkin as the E3 ligase, recombinant GST-RTP801 as
putative substrate, biotinylated ubiquitin, an E1 ubiquitin-
activating enzyme, and E2 ubiquitin-conjugating enzyme
UbcH7.6,25 As negative controls, we performed the same
reaction in the absence of either parkin, UbcH7, or GST-
RTP801, or in the presence of inactive truncated parkin. WB
analyses showed the appearance of high molecular weight
species corresponding to poly-ubiquitinated GST-RTP801
(HMW Ub-GST-RTP801) only when parkin and all other
constituents were present (Figure 1c, left lane).
RTP801 and parkin interact in cells. Next, we assessed
whether parkin and RTP801 interact in living cells. We
overexpressed RTP801 and GFP-tagged parkin in
HEK293 cells. After dithiobis succinimidyl propionate
(DSP) cross-linking and immunoprecipitation with normal
IgG or anti-RTP801, followed by WB, we observed co-
immunoprecipitation of parkin with RTP801 (Figure 1d).
We confirmed this interaction in the converse direction
by immunoprecipitating ectopic parkin and probing
for RTP801 (Supplementary Figure S3). Moreover, in
neuronal PC12 cells, co-immunoprecipitation in both
directions indicated that endogenous parkin interacts with
Figure 1 RTP801 is poly-ubiquitinated by parkin E3 ligase and degraded by the proteasome. (a) RTP801 is degraded by the proteasome. HEK293 cells were exposed for
4 h to 1 mM epoxomycin or 50mM chloroquine, and cell lysates were analyzed by western immunoblotting for RTP801 and a-actin (loading control). ut ¼ untreated.
(b) RTP801 is poly-ubiquitinated by parkin prior to proteasomal degradation. HEK293 cells were co-transfected with pCMS-eGFP RTP801, HA-ubiquitin and one of the pRK5-
myc constructs, either empty or containing parkin WT or parkin DR2. Twenty-four hours later, cultures were exposed to epoxomycin for 3 h prior to harvesting. RTP801 was
immunoprecipitated (IP) and immunocomplexes along with whole-cell lysates were analyzed by western immunoblotting (IB). Membranes were probed for HA, myc and
a-actin as a loading control. Membranes were reprobed with anti-RTP801 antibody to confirm that RTP801 was immunoprecipitated. Non-specific mouse immunoglobulins
were used as negative controls (m IgG). (HMW Ub-RTP801, high molecular weight ubiquitinated RTP801) (c) Parkin ubiquitinates RTP801 in a cell-free in vitro system.
Recombinant parkin E3 ligase (active full-length), truncated parkin (inactive), GST-RTP801, and UbcH7 E2 enzyme, were mixed and incubated as indicated along with
biotinylated ubiquitin, E1 enzyme, and ATP. RTP801 was immunoprecipitated, and immunocomplexes resolved in a western blot. The membrane was incubated with Avidin/
Biotin and then incubated with chemiluminiscent peroxidase substrate solution (upper panel). The same membrane was reprobed with an anti-RTP801 antibody (lower panel).
(HMWUb-RTP801, high molecular weight ubiquitinated RTP801) (d) Ectopic parkin physically interacts with ectopic RTP801. HEK293 cells were co-transfected either with the
pCMS-eGFP and pEGFP-C2 empty vectors or pCMS-eGFP RTP801 along with pEGFP-C2-parkin. Twenty-four hours later, cultures were treated with the cross-linking agent
DSP for 2 h at 41C, prior to harvesting. After RTP801 immunoprecipitation, the samples were analyzed by western immunoblotting for parkin to detect the interaction, and for
RTP801 as an IP control. (e and f) Reciprocal co-immunoprecipitation indicates interaction of endogenous parkin and RTP801 in cells. Neuronal PC12 cells were treated with
or without MG132 for 5 h as indicated, lysed and subjected to immunoprecipitation (IP) with control antibody (GFP), and either (e) anti-parkin or (f) anti-RTP801 antibodies.
Immunoprecipitates were analyzed by western immunoblotting with anti-parkin and anti-RTP801 as indicated. In (e) all samples were analyzed on the same blot, but irrelevant
intervening lanes were removed. In the right panel (f), the membrane was probed with a light chain-specific secondary antibody to diminish overlap of signal with
co-immunoprecipitated RTP801. In each panel (a, b, c, d, e and f), a representative western blot is shown from a pool of at least two independent experiments. Specific bands
are pointed out by arrows
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endogenous RTP801 (Figures 1e and f). This interaction
was observed when RTP801 was immunoprecipitated with
or without pretreatment with the proteasome inhibitor
MG132 (Figure 1f). Taken together, our results indicate
that RTP801 interacts with parkin and that parkin promotes
RTP801 poly-ubiquitination.
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Parkin regulates RTP801 levels in neuronal PC12 cells.
As parkin poly-ubiquitinates RTP801 both in vitro and in
cultured cells, we next asked whether parkin could directly
regulate RTP801 levels in a cellular model. Consistent with
this, transfected parkin significantly diminished basal levels
of RTP801 in neuronal PC12 cells (Figure 2a). Note that the
overall decrease in RTP801 was limited as transfection
efficiency of neuronal PC12 cells was only 15–20%.
Figure 2 Parkin regulates RTP801 protein in neuronal PC12 cells. (a) Ectopic parkin decreases RTP801 protein levels. Neuronal PC12 cells were transfected with pRK5-
myc or pRK5-myc Parkin constructs. Twenty-four hours later, cell extracts were harvested and subjected to western immunoblotting. Membranes were incubated with anti-
parkin and anti-RTP801 antibodies and then reprobed with anti-a-actin antibody, as protein loading control. Right panel shows densitometries representing values as mean±
S.E.M. of at least three independent experiments. Student’s t-test, **Po0.01 versus pRK5-myc. (b) Parkin does not regulate RTP801 transcriptionally. Neuronal PC12 cells
were transfected with pRK5-myc or pRK5-myc Parkin constructs. RNA was extracted 20 h later, and reverse transcription-qPCR was performed to quantify RTP801 mRNA
under the indicated conditions. Values represent mean± S.E.M. of at least three independent experiments. (c) Parkin knockdown results in elevated expression of RTP801
protein. Neuronal PC12 cells were infected with lentiviruses containing an empty vector (EV), a scrambled negative control shRNA, or four different parkin shRNAs (results for
shParkin A and B are shown on the left; knockdown by shParkin 1 33 and 2 was comparable to that with shA and shB). Cell lysates were assessed 4 days later for RTP801 and
parkin expression by western immunoblotting. Expression in each case was determined relative to the ERK1 loading control. Graph shows means of pooled data for all parkin
shRNAs± S.E.M. Student’s t-test, *Po0.05 and #Po0.05 versus shCt
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Several studies indicate that parkin has DNA-binding and
transcriptional activities.26,27 However, ectopic parkin did not
affect RTP801 mRNA levels in neuronal PC12 cells,
discounting the possibility that parkin regulates RTP801 at a
transcriptional level (Figure 2b).
To further assess the role of parkin in RTP801 expression,
we next diminished endogenous parkin expression with
specific shRNAs delivered by lentiviral infection. In neuronal
PC12 cells, shParkin elevated levels of RTP801 in compar-
ison with empty vector or scrambled control shRNA by about
65–70% (Figure 2c).
We also confirmed the effect of shParkin sequences A and
B on RTP801 expression by transient transfection in naive
PC12 cells by WB (Supplementary Figure S4a). Additionally,
NGF-differentiated PC12 cells transfected with these shRNAs
were analyzed by immunofluorescence (Supplementary
Figure S4b and c). Parkin knockdown (30–40%) significantly
elevated RTP801 immunostaining (25–35%), although not as
markedly as with lentiviral infection, owing to the lower
efficiency of transfection (Supplementary Figure S4).
Taken together, these results indicate that parkin regulates
endogenous RTP801 protein levels in neural cells and that
parkin knockdown leads to an increase in RTP801 protein
expression.
Parkin deficiency in vivo elevates RTP801. We next
tested how loss of parkin affects RTP801 protein levels in a
knockout (PaKO) mouse model with an exon 3 deletion in the
PARK2 gene.28 Although PaKO mice do not show a
conventional parkinsonian phenotype, they are a useful
model to study the role of parkin in protein regulation or
oxidative stress.29,30 By WB, we observed a modest but
significant accumulation of RTP801 in 8-month-old PaKO
mouse brains in comparison with wild-type littermates,
confirming in vivo that parkin loss results in elevated
RTP801 protein (Figure 3).
RTP801 accumulates in AR-JP patient fibroblasts and in
human postmortem PD brains with parkin mutations.
We next collected skin punches from AR-JP patients bearing
exon deletions in the PARK2 gene and from age-matched
controls (see Supplementary Table 1), and used these to
establish pure skin fibroblast cultures. By WB, we observed
that parkin mutant fibroblasts possessed a significantly
higher mean of RTP801 protein expression compared with
controls (Figure 4a).
We next tested RTP801 protein expression in control and
AR-JP fibroblasts after proteasome inhibition (epoxomycin) or
DNA damage (etoposide). Etoposide is reported to cause a
rapid and stable increase in RTP801 expression.31 After 4 h
with these stressors, which had no effect on viability (data not
shown), the RTP801 induction response of AR-JP cells was
approximately double that in cells from control patients
(Figure 4b). In conclusion, loss of parkin activity in mutant
fibroblasts significantly elevates RTP801 protein both under
basal and stressor conditions.
Our previous work demonstrated that RTP801 is upregu-
lated in NMþ neurons in the SNpc of sporadic PD patients.19
Therefore, we next examined RTP801 expression in SNpc
sections from patients bearing PARK2 mutations. Only two
cases with parkin mutations (one simple heterozygote, PKm1,
and one compound heterozygote, PKm2) were available from
the neurological tissue bank. We also included three cases of
sporadic PD and three non-PD cases (see Supplementary
Table 2). SNpc sections were immunostained for RTP801,
and proportions of NMþ neurons highly stained for RTP801
were blindly scored. As previously observed, there was a very
low proportion of RTP801þ nigral neurons in non-PD controls
and this was significantly increased in sporadic PD cases and
in the two cases with parkin mutations (Figures 5a and b). In
contrast, little or no RTP801 staining was observed in
cerebellum (a region little affected in PD32) from the same
patients (Supplementary Figure S5). Taken together, these
results indicate that parkin loss of function in humans
correlates with elevated RTP801, in both fibroblasts and
nigral neurons.
Parkin protects neuronal PC12 cells from exogenous
RTP801. Previous studies showed that RTP801 is pro-
apoptotic when overexpressed in neuronal PC12 cells17,19
and sympathetic neurons.20 This raised the question of
whether parkin protects from elevated RTP801 expression.
In neuronal PC12 cells, overexpressing wild-type parkin
alone did not affect survival, whereas the two parkin mutants,
Figure 3 RTP801 is elevated in parkin knockout mouse brains. Whole-brain
lysates from five 8-month-old PaKO mice and five wild-type littermates (WT) were
analyzed by western immunoblotting. Membranes were incubated with anti-RTP801
and anti-parkin antibodies, and subsequently reprobed with anti-a-actin antibody as
a loading control. Representative immunoblots are shown along with the
densitometries representing values as mean ± S.E.M. of at least three
independent membranes including all the samples. Student’s t-test with Welch’s
correction, *Po0.05 versus WT
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R42P (mutated in the UBL domain) or P437L (mutated in the
RING2 domain), with severely compromised E3 ligase
activity, showed a slight, but not significant decrease in
viability. When RTP801 was overexpressed alone, around
60% of the cells died, as previously reported.17,19 However,
ectopic wild-type parkin, but not the mutated parkin forms,
counteracted RTP801-induced cell death (Figure 6a).
To confirm that parkin protects from ectopic RTP801 by poly-
ubiquitinating it, we generated a non-ubiquitinable form of
RTP801 (RTP801 K-R), in which we substituted its six lysines
(K) with arginines (R). In neuronal PC12 cells, overexpressed
RTP801 K-R accumulated to a significantly higher degree than
overexpressed WT RTP801 (Supplementary Figure S6), which
is consistent with the role of ubiquitination and proteasomal
degradation in regulating RTP801 expression. Both WT and
RTP801 K-R induced similar levels of cell death (Figure 6b).
However, when these vectors were overexpressed along with
parkin, in contrast to its protection from WT RTP801, ectopic
parkin was incapable of preventing cell death induced by
RTP801 K-R (Figure 6b). These results are consistent with the
idea that RTP801 ubiquitination by parkin is necessary for
inhibiting RTP801 toxicity.
We next investigated whether parkin knockdown enhances
ectopic RTP801 toxicity. In NGF-differentiated PC12 cells,
parkin knockdown alone induced around 30–35% cell death
(Figure 6c). Ectopic RTP801 alone caused 50% cell loss,
whereas, interestingly, parkin knockdown significantly
enhanced such cell death to about 70% (Figure 6c).
Parkin diminishes RTP801 elevation and protects
against 6-OHDA. Parkin is protective in a variety of
neurodegeneration models, including the 6-OHDA model of
PD.13,14 Our previous studies indicate that induced RTP801
mediates neurotoxin-promoted death of dopaminergic
Figure 4 RTP801 is elevated in human fibroblasts derived from AR-JP patients with parkin mutations. (a) RTP801 is elevated in fibroblasts from parkin mutant AR-JP
patients. Extracts from human primary fibroblasts derived from six diagnosed parkin mutant AR-JP patients (PKm AR-JP) and six control individuals (Ct) were subjected to
western immunoblotting. Membranes were probed with antibodies against parkin and RTP801 and reprobed for a-actin (loading control). Representative immunoblots are
shown along with the densitometries for RTP801 signals from at least three independent membranes including all the samples. Student’s t-test, *Po0.05 versus control
individuals. (b) Parkin mutant fibroblasts exposed to epoxomycin or etoposide show elevated RTP801 accumulation. The same human primary fibroblasts were treated for 4 h
with 1 mM epoxomycin or 25mM etoposide before being harvested. The resulting extracts were analyzed by western immunoblotting. Membranes were incubated with
antibodies against parkin and RTP801, and subsequently reprobed with anti-a-actin antibody as a loading control. The graph shows densitometries for RTP801 signals from at
least three independent membranes. Student’s t-test, *Po0.05 versus control untreated, þPo0.05 versus control epoxomycin, $Po0.05 versus control etoposide; ANOVA
with Bonferroni’s multiple comparison test, #Po0.05 and ##Po0.01 versus control untreated. ut ¼ untreated
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neurons in vitro and in vivo.19,20,23 Therefore, we next
determined whether there is a relationship between parkin
and RTP801 levels in the neuronal PC12 cell 6-OHDA
model. 6-OHDA significantly induced endogenous RTP801
protein19 and endogenous parkin levels were diminished
by nearly half33 (Figure 7a). Moreover, we found that
transfecting neuronal PC12 cells with WT parkin, but not
the R42P and P437L parkin mutants, significantly decreased
elevation of RTP801 protein induced by 6-OHDA (Figure 7b).
To verify our findings with primary neurons, we turned to
sympathetic neurons, a population that degenerates in PD.
We observed parkin knockdown by about 50% in cultured rat
Figure 5 RTP801 is elevated in parkin mutant NMþ nigral neurons. Paraffin-embedded sections of SNpc from control individuals (CT1, CT2 and CT3), parkin simple
heterozygous mutant patient (PKm1), parkin compound heterozygous mutant (PKm2) and sporadic PD patients (SPD1, SPD2 and SPD3) were immunostained for RTP801
(grey-blue). Note the presence of neuromelanin granules (brown) in the somas of dopaminergic neurons. Arrows point to highly stained NMþ nigral neurons. The percentage
of NMþ and RTP801þ neurons versus total NMþ neurons was scored for each case, and results are represented in the graph. Student’s t-test, *Po0.05 versus control
individuals. In total, 150–500 neurons were evaluated per section
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Figure 6 Parkin protects from RTP801-induced cell death. (a) Ectopic parkin WT protects from the cell death caused by RTP801. Neuronal PC12 cells were co-transfected
with pRK5-myc, pRK5-myc Parkin WT, pRK5-myc Parkin R42P or pRK5-myc Parkin P437L constructs, along with either pCMS-eGFP or pCMS-eGFP RTP801 constructs.
Twenty-four hours later, eGFPþ surviving cells were scored under fluorescence microscopy. Values represented as mean ± S.E.M. of at least three independent
experiments in triplicate in each condition. ANOVA Bonferroni’s multiple comparison test, ***Po0.001 versus pRK5-myc/pCMS-eGFP, ###Po0.001 versus pRK5-myc/
pCMS-eGFP RTP801. (b) Parkin protects neuronal PC12 cells from RTP801-induced cell death by mediating its ubiquitination. In NGF-differentiated PC12 cells, we co-
transfected pRK5-myc or pRK5-myc Parkin, along with one of the pCMS-eGFP constructs, either empty or containing RTP801 or RTP801 K-R. Twenty-four hours later, cells
were fixed and immunostained, and eGFPþ surviving cells were scored under fluorescence microscopy. Values represented as mean ± S.E.M. of at least three
independent experiments in triplicate in each condition. ANOVA Bonferroni’s multiple comparison test, ***Po0.001 versus pRK5-myc/pCMS-eGFP, ###Po0.001 versus
pRK5-myc/pCMS-eGFP RTP801. (c) Knocking down parkin exacerbates RTP801-mediated cell death. PC12 cells differentiated with NGF were first transfected with a
scrambled negative control shRNA (shCt) or two different parkin shRNAs (shParkin A or B), and after 72 h, cultures were transfected with pCMS-eGFP or pCMS-eGFP
RTP801 constructs. Twenty-four hours after the second transfection, ZsGreenþ /eGFPþ surviving cells were scored under fluorescence microscopy. Values represented as
mean± S.E.M. of at least three independent experiments in triplicate in each condition. ANOVA with Bonferroni’s multiple comparison test, ***Po0.001 versus shCt/pCMS-
eGFP, ###Po0.001 versus shCt/pCMS-eGFP RTP801. In each panel, values represent mean± S.E.M. of, at least, three independent experiments with four replicates per
condition
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sympathetic neurons with lentivirally expressed shRNAs
against parkin. This raised basal RTP801 levels by about
the same magnitude (Figure 7c). Moreover, parkin knock-
down in these neurons significantly increased RTP801 protein
induction by 6-OHDA (Figure 7c). These results support our
observations in neuronal PC12 cells that RTP801 knockdown
increases RTP801 levels and extend them to show that parkin
knockdown exacerbates the RTP801 response to 6-OHDA in
neurons (see Figure 2c).
We next examined whether ectopic parkin, which
decreases endogenous RTP801 upregulation (Figures 7a
and b), is neuroprotective in the 6-OHDA model. In neuronal
PC12 cells, overexpressed WT parkin, but not the two parkin
mutants, significantly reduced 6-OHDA-induced death
(Figure 7d). Note that the parkin P437L mutant decreased
cell viability after 6-OHDA exposure, possibly by acting as a
dominant-negative.
Finally we explored whether parkin knockdown sensitizes
neuronal PC12 cells to 6-OHDA toxicity and whether this
depends on RTP801. Parkin knockdown induced cell death in
untreated cultures (see also Figure 6c) and enhanced
6-OHDA-promoted toxicity (Figure 7e and Supplementary
Figure S7). When we simultaneously knocked down parkin
and RTP801, we prevented parkin knockdown-induced cell
death and its sensitization to 6-OHDA. These findings indicate
that the toxic effects of parkin loss of function require the
presence of RTP801.
Taken together, these results indicate that in cellular
models of PD, parkin protects, at least in part, by preventing
RTP801 elevation.
Discussion
Here, we identified a new substrate of parkin. We show that
parkin mediates RTP801/REDD1 poly-ubiquitination, facil-
itates its proteasomal degradation and that endogenous
parkin and RTP801 interact in living cells. We also show that
parkin loss of function elevates RTP801 protein in cellular and
animal models. This is supported by observations of elevated
RTP801 in both postmortem PD brains and fibroblasts from
patients with parkin mutations. Furthermore, overexpression
of WT parkin, but not its inactive mutated forms, protects
neuronal cells from death when RTP801 is overexpressed or
induced with 6-OHDA. We thus propose that one mechanism
by which parkin exerts neuronal protection is by preventing
accumulation of lethal RTP801 protein levels.
Our data indicate that RTP801 is poly-ubiquitinated and
targeted to the ubiquitin proteasome system (UPS). These
results agree with others that RTP801 degradation depends
on the UPS.21–23 UPS alterations are a common feature in
cellular and animal models of PD and in the disease itself.34,35
Based on our results, UPS impairment associated with PD
could contribute, in part, to RTP801 elevation in both sporadic
PD and AR-JP.
We showed that parkin poly-ubiquitinates RTP801, both
in vitro and in vivo. The only presently described E3 ligase for
REDD1/RTP801 is CUL4A-DDB1 in HEK293 and MCF-7
cells.21 However, Zhao et al.36 could not confirm this result.
Whether Cul4A-DDB1 is relevant in the context of PD is
presently unknown.
Parkin and its ligase activity have been linked to both
familial and sporadic PD. Mutations in PARK2,5,6 S-nitrosyla-
tion7 and oxidative8 or dopaminergic stress9 critically com-
promise parkin solubility and E3 ligase activity. Parkin
enzymatic impairment has been proposed to produce toxic
accumulation of its substrate proteins, which in turn causes
neurodegeneration.
Many proteins have been proposed as parkin substrates;
however only a few have been confirmed. Dawson et al.37
proposed that a ‘true’ parkin substrate should accumulate in both
AR-JP and sporadic PD as well as in animal models of parkin
inactivation such as PaKO mice and the MPTP toxin model.37
Our previous19,23 and present work appears to fulfill these
requirements37 for RTP801. Additional parkin substrates have
been reported38 and these, along with RTP801, could represent
accumulated proteins that contribute to neuron degeneration
associated with parkin loss of expression or function.
We found a relatively modest, but significant, increase of
RTP801 in PaKO mice. These animals have motor and non-
motor behavioral impairments,39 deficient synaptic transmis-
sion,40 reduced mitochondrial respiration and increased
oxidative damage,41 and loss of DA neurons after 2 years of
age.42,43 The PaKO mice examined in our study were only 8-
month old. Our data raise the possibility that early RTP801
accumulation could contribute to the impairments cited above
and to neuron death at an older age. Also, in younger PaKO
mice, other ligases may compensate for parkin loss and
maintain levels of substrate proteins, such as RTP801. The
relatively small increase in RTP801 seen in 8-month-old
PaKO mice is also consistent with, and could potentially
account for, the lack of neuron death at this age.
In postmortem sections from two PD cases with PARK2
gene mutations, NMþ neurons showed higher levels of
RTP801 expression. One case involved compound hetero-
zygous mutations and behaved as a homozygous parkin
mutant, with early onset of disease. However, the second
case had a simple heterozygous mutation in the parkin gene,
with late disease onset. Both cases showed elevated RTP801
levels as in sporadic cases. This could reflect findings that loss
of only one copy of the parkin gene can be a risk factor for
PD.10,44 To extend our results, fibroblasts from six AR-JP
patients with PARK2 gene mutations were assessed. Cul-
tured skin fibroblasts are very useful to study genetic PD
mechanisms.45 We reasoned that mutations in the PARK2
gene should influence RTP801 turnover in cells in addition to
neurons. We observed that RTP801 protein levels approxi-
mately doubled in AR-JP patient fibroblasts compared with
controls, and that the RTP801 response to etoposide or
epoxomycin was exaggerated in AR-JP fibroblasts. This is
consistent with the idea that parkin loss of function elevates
RTP801 in both neuronal and non-neuronal cells. However,
as fibroblasts are proliferative, RTP801 does not induce their
cell death as it does in non-dividing neurons.17,19
Our previous work demonstrated that RTP801 was
upregulated in cellular and animal models of PD and in
NMþ nigral neurons of sporadic PD patients. It also showed
that RTP801 elevation is sufficient to mediate neuron cell
death, and that RTP801 is required for neuron death in several
PD models.19 Hence, as parkin loss of function leads to
RTP801 elevation, it is logical to suggest that this effect
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contributes to neuronal degeneration and cell death in the
context of PD. RTP801 protein elevation can be the end point
of two different processes; one being gene activation by PD-
associated neuronal stress,18,19 and the other, defective
RTP801 degradation due to impaired parkin activity. RTP801
may therefore contribute, with other parkin substrates, to
neuron death and degeneration in both sporadic and parkin-
associated PD.
Parkin protects from neuron toxicity associated with
multiple stressors including mutant alpha synuclein,46 kainate
acid excitotoxicity12 as well as dopamine47 and 6-OHDA.14
In consonance with this, we observed that WT parkin, but not
its mutated forms, decreased RTP801-induced cell death of
neuronal PC12 cells. Significantly, the neuroprotective effect
of parkin was lost for non-ubiquitinable form of RTP801.
Ectopic parkin protected against 6-OHDA, and this protection
was accompanied by a decrease in RTP801 protein. More-
over, parkin knockdown diminished cell survival, and sensi-
tized cells against 6-OHDA. Interestingly, RTP801
knockdown abrogated this sensitization and restored cell
survival. These results strongly suggest that parkin is
protective, at least in part, by mediating RTP801 proteasomal
degradation. Neuroprotective effects of parkin appear due, at
least in part, to its effects on mitochondria, by regulating
cytochrome c release and apoptosis.48 A portion of RTP801
protein is also translocated to mitochondria.49 This suggests
that clearance of RTP801 by parkin may have direct effects on
mitochondrial function as well as on mTOR/Akt signaling.
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Abrogation of RTP801 expression with shRNAs or phar-
macologic agents has been demonstrated to be a useful
strategy for neuroprotection. In cellular models of PD,
RTP801 shRNAs protected both sympathetic neurons and
neuronal PC12 cells from neurotoxins.19 RTP801 knockdown
also has been successful in treating ocular diseases like
macular degeneration.50 Pharmacologically, rapamycin, by
partially inhibiting mTOR, interferes with RTP801 translation
and is protective in cellular and animal models of PD.23 Our
data indicate that parkin contributes to decreasing cellular
RTP801 protein levels. Therefore, means to elevate parkin
levels or activity in neurons would be anticipated to provide
neuroprotection, at least, in part, via degradation of RTP801.
In conclusion, our work in cellular and animal models and in
human samples strongly indicates that RTP801 is a substrate
of parkin and that RTP801 elevation due to parkin loss of
function in both AR-JP and sporadic PD may contribute to
neurodegeneration. Any genetic conditions or stress situa-
tions that compromise parkin activity have the potential to
produce a toxic accumulation of RTP801. This is relevant to
design of therapeutic approaches to promote neuron survival
and block neurodegeneration in both sporadic and AR-JP.
Materials and methods
Antibodies, plasmids and materials. Rabbit polyclonal anti-RTP801
antibody (used for WB and immunohistochemistry) was purchased from
Proteintech Group (Chicago, IL, USA). Mouse monoclonal anti-RTP801 (used
for immunoprecipitation) was purchased from Bethyl Laboratories (Montgomery,
TX, USA). Monoclonal mouse antibody anti-parkin used for WB and
immunohistochemistry was purchased from Abcam (Cambridge, UK). Monoclonal
mouse anti-parkin antibody (used for immunoprecipitation), polyclonal rabbit anti-
myc (used for WB), monoclonal mouse anti-myc (used for immunoprecipitation)
and anti-HA tag were obtained from Cell Signaling Technology (Danvers, MA,
USA). Mouse monoclonal antibody against GFP and rabbit polyclonal antibodies
against parkin and ERK1 were obtained from Santa Cruz Biotechnology (Dallas,
TX, USA). Anti-a-actin antibody was purchased from MP Biomedicals (Santa Ana,
CA, USA). Goat anti-mouse or anti-rabbit secondary antibodies conjugated to
horseradish peroxidase were obtained from Pierce Thermo Fisher Scientific
(Rockford, IL, USA). Goat anti-mouse or anti-rabbit secondary antibodies
conjugated with Alexa 488 or Alexa 568 were purchased from Life Technologies
(Grand Island, NY, USA). Peroxidase-conjugated goat anti-IgG light chain-specific
secondary antibody was obtained from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA).
The pCMS-eGFP RTP801 construct was generated as previously described.19
The pcDNA3 HA-ubiquitin construct was purchased from Addgene (Cambridge,
MA, USA). The constructs pEGFP-C2, pEGFP-C2-parkin, pRK5-myc, pRK5-myc
Parkin and the parkin point mutation pRK5-myc Parkin P437L were a kind gift from
Dr. Serge Przedborski (Columbia University, New York, NY, USA). The parkin point
mutant pRK5-myc Parkin R42P and the parkin deletion pRK5-myc ParkinDR2 were
kindly provided by Dr. Leonidas Stefanis (Academy of Athens, Biomedical Research
Foundation, Athens, Greece). All constructs were verified by DNA sequencing.
Epoxomycin, MG132 and etoposide were purchased from Calbiochem Merck
Millipore (Billerica, MA, USA), Chloroquine and CHAPS were obtained from
Sigma-Aldrich (St. Louis, MO, USA) and 6-OHDA was purchased from Tocris
Bioscience (Bristol, UK).
Directed mutagenesis. The pCMS-eGFP RTP801 K-R construct was
obtained from the pCMS-eGFP RTP801 construct by mutating all the lysines (K) to
arginines (R) using the QuickChange Lightning II multi site-directed mutagenesis
(Agilent Technologies, Santa Clara, CA, USA), with the following primers: K126R,
50-GAGCCAGGTGGGCAGGGAACTCCTGC-30; K152R, 50-GTGTGGAGCAAGGC
AGGAGCTGCCATAGTGT-30; K185R, 50-GCCTCTGGCCCAGGATCCAGGGCC
T-30; K215R-K216R-K217R, 50-CACCGGCTTCAGAGTCATCAGAAGGAGACT
CTACAGCTCCGAG-30 All new constructs were verified by DNA sequencing.
shRNA production. shG-scrambled control RNA and shRTP801 were
generated as previously described.51 Two different parkin shRNAs were prepared
in a ZsGreen expressing pSIREN vector using the Knockout RNAi Systems
(Clontech Laboratories, Mountain View, CA, USA) according to the manufacturer’s
instructions, based on the following sequences: shParkin A, 50-AACAACAGA
GTATCGTTCACA-30; shParkin B, 50-ATCGTTCACATAGTACAGAGA-30; shParkin
1, 50-AGCTCCATCACTTCAGGATCC-30 (as described in Sun et al.33); shParkin 2,
50-ATCACCTGACAGTACAGAACT-30. The scrambled negative control shRNA
(shCt) was provided by the same kit with the sequence: 50-GTGCGTTGCTAG
TACCAAC-30. shParkins A, B and 2 were specific for rattus norvegicus parkin,
whereas shParkin 1 was specific for rat and mouse.
Lentivirus preparation. Viral particles for neuronal PC12 infection were
prepared as previously described.33
Cell culture. PC12 cells were cultured and treated with NGF as described
previously.52 For NGF treatment, the cells were cultured in RPMI 1640 medium (Gibco
Life Technologies, Grand Island, NY, USA) supplemented with 1% heat-inactivated
horse serum (Sigma-Aldrich), penicillin/streptomycin, and 50 ng/ml recombinant human
b-NGF (Alomone Labs, Jerusalem, Israel; or kindly provided by Genentech, South
San Francisco, CA, USA) for 7–8 days, in a 7.5% CO2 atmosphere at 37 1C.
Figure 7 Parkin decreases elevation of RTP801 and protects from 6-OHDA. (a) RTP801 and parkin protein levels after 6-OHDA exposure. Neuronal PC12 cells were
exposed to 50 or 100mM 6-OHDA for 16 h. Cell extracts were subjected to western immunoblotting. Membranes were probed with antibodies against parkin and RTP801, and
then reprobed for a-actin as protein loading control. Right panels represent quantification of parkin and RTP801 densitometric values (mean± S.E.M.) normalized to a-actin,
of three independent experiments. ANOVA with Bonferroni’s multiple comparison test, ***Po0.001 versus untreated control cultures. (b) Ectopic parkin decreases 6-OHDA-
induced RTP801 protein. Neuronal PC12 cells were transfected with pRK5-myc, pRK5-myc Parkin WT, pRK5-myc Parkin R42P or pRK5-myc Parkin P437L plasmids. Forty-
eight hours later, cultures were exposed to 100mM 6-OHDA for 16 h. Cell extracts were harvested and subjected to western immunoblotting. Membranes were incubated with
anti-parkin and anti-RTP801 antibodies. The same membranes were then reprobed with anti-a-actin antibody as loading control. Upper panel shows RTP801 densitometries
representing values as mean± S.E.M. of at least three independent experiments. ANOVA with Bonferroni’s multiple comparison test, *Po0.05 versus untreated pRK5-myc,
##Po0.01 versus 6-OHDA-treated pRK5-myc. (c) Parkin knockdown increases RTP801 levels induced by 6-OHDA. Rat sympathetic neurons were infected with lentiviruses
containing either a scrambled negative control shRNA (shCT) or a pool of three different shRNA constructs against parkin (shParkin). Six days later, cultures were treated with
5mM 6-OHDA for 16 h. Cell extracts were harvested and subjected to western immunoblotting. Membranes were probed with antibodies against parkin, RTP801 and a-actin
as a loading control. Upper panel shows RTP801 quantification (mean± S.E.M.) normalized to a-actin, of three independent experiments. ANOVA with Bonferroni’s multiple
comparison test, **Po0.01 versus untreated shCT, #Po0.05 versus 6-OHDA-treated shCT. (d) Parkin protects from 6-OHDA-induced cell death. Neuronal PC12 cells were
co-transfected with pRK5-myc/pCMS-eGFP, pRK5-myc Parkin WT/pCMS-eGFP, pRK5-myc Parkin R42P/pCMS-eGFP or pRK5-myc Parkin P437L/pCMS-eGFP constructs
(4:1) and 48 h later cultures were treated with 100 mM 6-OHDA. Twenty-four hours after 6-OHDA exposure, eGFPþ surviving cells were scored under fluorescence
microscopy. Values represent mean ± S.E.M. of at least three experiments with six replicates in each condition. ANOVA with Bonferroni’s multiple comparison test,
***Po0.001 versus untreated pRK5-myc/pCMS-eGFP, ##Po0.01 and ###Po0.001 versus 6-OHDA-treated pRK5-myc/pCMS-eGFP. (e) Parkin knockdown sensitizes to
6-OHDA-induced cell death in an RTP801-dependent manner. Neuronal PC12 cells were transfected with parkin shRNA (shParkin B) or its scrambled negative control (shCt),
along with a shRNA sequence against RTP801 (shRTP801) or its corresponding shRNA scrambled control sequence (shG). After 72 h of transfection, cultures were treated
with 100mM 6-OHDA. Twenty-four hours after treatment cells were fixed and ZsGreenþ /eGFPþ surviving cells were scored under fluorescence microscopy. Values
represent mean ± S.E.M. of at least three experiments with three replicates in each condition. ANOVA with Bonferroni’s multiple comparison test, ***Po0.001 versus
untreated shCt/shG, ###Po0.001 versus untreated shParkin B/shG, þ þ þPo0.001 versus 6-OHDA-treated shCt/shG and $$$Po0.001 versus 6-OHDA-treated shParkin
B/shG. ut ¼ untreated
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Neonatal rat superior cervical ganglion sympathetic neurons were cultured as
previously described.19,53
HEK293 cells were maintained in DMEM medium (Gibco Life Technologies)
supplemented with 10% fetal calf serum (Gibco Life Technologies) and penicillin/
streptomycin (Gibco Life Technologies) in a 5% CO2 atmosphere at 37 1C.
Human fibroblasts derived from six diagnosed AR-JP patients with PARK2
dysfunctional mutations and six control individuals were cultured in DMEM medium
supplemented with 10% fetal calf serum and penicillin/streptomycin in a 5% CO2
atmosphere at 37 1C. These fibroblasts were obtained from the Neurology Service-
Movement Disorders Biorepository (IDIBAPS, Hospital Clinic, Universitat de
Barcelona, Barcelona, Catalonia, Spain). Fibroblasts were used between 5 and 6
passages in vitro.
Transfection, treatments and viral infection. Neuronal PC12 and
HEK293 cells were transfected with Lipofectamine 2000 (Invitrogen Life
Technologies, Grand Island, NY, USA) according to the manufacturer’s instructions.
6-OHDA treatments were performed after 6–7 days of culture in NGF-
differentiated PC12, and at day in vitro (DIV) 9 in primary rat sympathetic neuronal
cultures. Medium was changed right before treatments.
Neuronal PC12 cells were infected at DIV3 and at a multiplicity of infection (MOI) of 3.
Primary neonatal rat SCG sympathetic neurons were infected at DIV 3 and at a MOI of
2, with lentiviral particles containing a pool of three different shRNAs constructs against
rat parkin (shParkin) or a scrambled control sequence (shCT), both obtained from Santa
Cruz Biotechnologies. After 18–20 h of infection, medium containing remaining lentiviral
particles was removed and replaced by fresh medium.
Quantitative reverse transcription-PCR. Each sample of total RNA
was isolated from neuronal PC12 cells by using the High Pure RNA Isolation Kit
(Roche Diagnostics Corporation, Indianapolis, IN, USA). cDNA was transcribed
from total RNA with the Transcriptor First Strand cDNA Synthesis Kit Roche
Diagnostics Corporation. Specific primers used for quantitative PCR amplification
were as follows: RTP801 forward primer, 50-GCTCTGGACCCCAGTCTAGT-30;
RTP801 reverse primer, 50-GGGACAGTCCTTCAGTCCTT-30; a-actin forward
primer, 50-GGGTATGGGTCAGAAGGACT-30; a-actin reverse primer, 50-GAGGC
ATACAGGGACAACAC-30. Quantitative PCR was performed with a 7500 Real
Time PCR System (Applied Biosystems, Foster City, CA, USA) using equal
amounts of cDNA template for quantitative PCR analysis of RTP801, normalized
by a-actin. The genes analyzed in this study were examined by the relative
expression by means of DDCT.
WB analysis. Whole-cell extracts or 8-month-old PaKO mouse total brain
lysates were collected, prepared and analyzed, as previously described.19,28
Chemoluminiscent images were acquired with a LAS-3000 Imager (Fujifilm,
Valhalla, NY, USA).
Immunoprecipitation. In the experiments where we immunoprecipitated
ectopic RTP801 and parkin, cell extracts were collected with cell lysis buffer (Cell
Signaling Technology) and pre-cleared with protein A/G sepharose beads
(Immunoprecipitation Starter Pack; GE Healthcare Bio-Science, Pittsburgh, PA,
USA) for 1 hour at 4 1C. Pre-cleared cell lysates were incubated overnight at 4 1C
in rotation, with the corresponding antibody or a normal immunoglobulin (Santa
Cruz Biotechnology) as a negative control. Immunocomplexes were incubated with
BSA-blocked protein A/G sepharose beads for 4 h at 4 1C in rotation. Then the
beads were centrifuged and washed five times with CHAPS buffer (Tris 50mM; pH
7.4, NaCl 150mM, MgCl2 10mM, CHAPS 0.4%), and the immunocomplexes were
collected and subjected to WB. The cross-linking agent DSP (Gibco Life
Technologies) was used according to the manufacturer’s instructions. In order to
immunoprecipitate endogenous RTP801 and parkin, cell extracts were collected
with cell lysis buffer and incubated overnight at 41C in rotation, with the
corresponding antibody or a control antibody (GFP) as a negative control.
Immunocomplexes were incubated with protein A (parkin) or protein G (RTP801)
for 2 h at 4 1C in rotation. Then the beads were centrifuged and washed four times
with cell lysis buffer, and the immunocomplexes were resolved in a western blot.
In vitro ubiquitination. The assay was performed by using the
Ubiquitinylation Kit according to the manufacturer’s instructions (Enzo Life
Sciences, Farmingdale, NY, USA) with slight modifications. Briefly, (20mM Tris-
HCl; pH 7.5, 1 mM dithiothreitol, 20 U/ml inorganic pyrophosphatase, 5mM Mg-
ATP, 0.1mM His6-tagged recombinant human ubiquitin-activating enzyme E1,
2.5mM biotinylated ubiquitin), His6-tagged recombinant human ubiquitin-conjugat-
ing enzyme UbcH7 E2 (Enzo Life Biosciences), His6-tagged recombinant human
parkin full-lenght (Merck Millipore), N-terminal GST-tagged recombinant human
RTP801 full-length (Novus Biologicals, Cambridge, UK), and GST-tagged
recombinant human truncated and inactive parkin (1-387) (Novus Biologicals),
were added to the reaction buffer, as referred in each condition, and then
incubated at 37 1C for 90min. RTP801 was immunoprecipitated as described
above, and equal volumes of each sample were subjected to WB. The blotted
membranes were probed for biotinylated ubiquitin using Avidin/Biotin-Horseradish
Peroxidase (Ultra-sensitive ABC staining kit; Thermo Fisher Scientific, Waltham,
MA, USA) or by anti-RTP801 antibody (Proteintech Group).
Immunofluorescence. Neuronal PC12 cells were fixed with 4% parafor-
maldehyde, stained and observed under fluorescence microscopy, as previously
described.20 Fluorescence from stained cells was quantified with ImageJ software
(NIH). Fluorescence for parkin staining (in red) or for RTP801 staining (in red) in
each single transfected cell (ZsGreenþ ) with shParkin A and B was quantified
and normalized with the fluorescence signal from non-transfected cells, and
percentages were compared with the ones obtained with shControl (shCt). Cells
were counter-stained with Hoescht 33342 (Invitrogen Life Technologies) to
visualize the nucleus. In survival assays, transfected viable cells were scored by
strip counting, as previously described.19
Immunohistochemistry of human sections. Paraffin-embedded sec-
tions of postmortem human SNpc and cerebellum from control individuals, parkin
heterozygous mutant PD patients, and sporadic PD patients, were obtained from
the Neurological Tissue Bank (Biobank-HC-IDIBAPS) and stained as previously
described.19
Statistics. All experiments were performed at least in triplicate, and results are
reported as means±S.E.M. Student’s t-test was performed as appropriate and
indicated in the figure legends, mostly as unpaired, two-tailed sets of arrays and
presented as probability P-values, or otherwise stated in the figure legends. One-
way or two-way ANOVA with Bonferroni’s multiple comparison test were
performed to compare multiple groups.
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